Background {#Sec1}
==========

Unchanged low-dose radiotherapy (RT) for benign diseases accounts for 8--10% of all RT procedures in Germany. As many as 70% of these indications represent painful disorders in the locomotor system \[[@CR1]\].

Previous radiobiological studies have shown that low doses of radiation can favorably influence various inflammatory pathways and immune components, such as endothelial cells, mononuclear and polynuclear leukocytes, and macrophages \[[@CR2]\].

In clinical practice, single doses of 0.5 to 1.0 Gy and total doses of 3.0 to 6.0 Gy per series are used. The aims of this retrospective clinical quality assessment were to analyze the therapeutic effect of low-dose irradiation immediately after completion of RT and during follow-up, and to identify possible prognostic factors in patients with painful arthrosis and enthesopathies.

Methods {#Sec2}
=======

Patients and treatment {#Sec3}
----------------------

Between January 2014 and December 2015, patients with painful arthrosis and enthesopathies were recruited for this retrospective clinical quality assessment. All patients provided informed consent regarding radiotherapy and participation in this clinical quality assessment prior to enrollment. RT was applied with a linear accelerator using 6 and 15 MV photon fields. Single doses of 0.5 Gy were administered five times a week, for a total dose of 3.0--5.0 Gy.

Pain was measured before and immediately after RT (early response) using a 10-point visual analogue scale (VAS; 0, no pain to 10, strongest pain) \[[@CR3]\]. A VAS score of 0--2 is comparable to the "von Pannewitz" score pain-free and significantly improved; therefore, we defined a VAS score of 0--2 as a good response following RT. Pain relief was measured during follow-up.

The assessment of long-term efficacy was carried out by telephone survey. All 598 patients were available by phone. All results were recorded in an Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheet and then transferred to SPSS (IBM Corporation, Armonk, NY, USA) for evaluation after completion of the survey.

Statistical analysis {#Sec4}
--------------------

All data were stored and analyzed using the SPSS statistical package 23.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were computed for continuous and categorical variables, including median and interquartile ranges (IQR) of ordinal variables, mean and standard deviations of continuous variables, and frequencies and relative frequencies of categorical factors. The Wilcoxon signed-rank test was used to test for differences in continuous and categorical variables within the groups. To test for between-group differences, the Mann--Whitney U test was used for continuous variables and Fisher's exact test for categorical variables, as appropriate. All *P*-values were two-sided statistical tests, and *P* \< 0.05 was considered significant. A Cox proportional hazards model was used for multivariate analysis to assess the independence of pain on prognostic factors for a good response at follow-up.

Results {#Sec5}
=======

Patients {#Sec6}
--------

A total of 598 evaluable patients (394 women, 204 men) with a mean age of 61.4 years (range 33--81 years) were recruited for the study. The following diagnoses were given: calcaneodynia (*n* = 194), shoulder syndrome (*n* = 135), arthrosis of the hand including rhizarthritis (*n* = 95), elbow syndrome (*n* = 60), trochanteric syndrome (*n* = 54), gonarthrosis (*n* = 30), and coxarthrosis (*n* = 30). A total of 507 patients were pre-treated prior to RT, including local injections, physiotherapy, NSAIDs, and shoe insoles. Ninety-one patients were irradiated without previous treatment. Patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Patient and treatment characteristicsDiagnosisNumberMean age, years (range)Female/maleOne seriesTwo seriesThree seriesMedian follow-up, months (range)Calcaneodynia19457.7 (38--79)137/5711275738 (29--46)Shoulder syndrome13565.7 (46--81)73/627254939 (30--46)Arthrosis of the hand9565.4 (35--80)69/265140439 (30--45)Elbow syndrome6052.9 (33--75)33/273126338 (29--44)Trochanteric syndrome5463.7 (41--78)45/93316536.5 (30--45)Gonarthrosis3062.4 (46--80)17/131910137.5 (30--44)Coxarthrosis3064.9 (51--78)20/10218138 (30--47)All patients59861.4 (33--81)394/2043392293038 (29--47)

Treatment and series {#Sec7}
--------------------

RT was fractionated into 6 × 0.5 Gy in 34 patients and with 10 × 0.5 Gy in 564 patients. The standard was fractionation of 10 × 0.5 Gy. In 34 cases, due to individual reasons, RT was fractionated as 6 × 0.5 Gy. RT was performed as one series in 339 patients, two series in 229 patients, and three series in 40 patients based on insufficient remission of pain. RT of shoulder, hip, knee joints, and trochanteric syndrome was performed with opposing photon fields, and RT of the heels, hands, and elbows was performed with single photon fields.

VAS before and immediately upon completion of RT {#Sec8}
------------------------------------------------

The median VAS score was 7.0 (IQR 2) before treatment and 5.0 (IQR 4) immediately upon completion of RT (*p* \< 0.001). The results of RT for patients with different diagnoses are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Median VAS scores before and at completion of RT (Interquartile Range)DiagnosisBefore RT (interquartile range)At completion of RT (interquartile range)*P*-valueCalcaneodynia7.0 (2)5.0 (3)\<0.001Shoulder syndrome7.0 (2)5.0 (3)\<0.001Arthrosis of the hand7.0 (3)5.0 (4)\<0.001Elbow syndrome8.0 (2)6.0 (4)\<0.001Trochanteric syndrome8.0 (2)4.0 (4)\<0.001Gonarthrosis7.0 (1)6.0 (4)\<0.001Coxarthrosis8.0 (2)6.0 (4)0.002All patients7.0 (2)5.0 (4)\<0.001

VAS follow-up {#Sec9}
-------------

Twelve weeks after radiotherapy (*n* = 339), the median VAS score was 4.0 (IQR 4). After a median follow-up of 38 months (range 29--47 months), the median VAS score was 1.0 (IQR 4; *p* = 0.001).

Good response immediately upon completion of RT {#Sec10}
-----------------------------------------------

A good response was achieved immediately upon completion of RT in 83/598 patients (13.9%) and 12 weeks after radiotherapy in 119/339 patients (35.1%; *p* \< 0.001).

Good response at follow-up {#Sec11}
--------------------------

A good response was achieved within a median follow-up of 38 months in 373/598 patients (62.4%). This is a significant improvement over the results immediately upon completion of RT and 12 weeks after RT (*p* \< 0.001). Results for the different diagnoses are given in Table [3](#Tab3){ref-type="table"}.Table 3Proportion of good responses at completion of RT and follow-upDiagnosisAt completion of RT, %At follow-up, %*P*-valueCalcaneodynia13.9 (27/194 patients)85.6 (166/194 patients)\<0.001Shoulder syndrome17.7 (24/135 patients)53.3 (72/135 patients)\<0.001Arthrosis of the hand9.5 (9/95 patients)50.5 (48/95 patients)\<0.001Elbow syndrome15 (9/60 patients)70 (42/60 patients)\<0.001Trochanteric syndrome16.7 (9/54 patients)57.4 (31/54 patients)\<0.001Gonarthrosis10 (3/30 patients)20 (6/30 patients)0.317Coxarthrosis6.7 (2/30 patients)26.7 (8/30 patients)0.014All patients13.9 (83/598 patients)62.4 (373/598 patients)\<0.001

Rate of recurrence after a good response during follow-up {#Sec12}
---------------------------------------------------------

Compared to immediately after RT, 15 of the 83 patients (18.1%) with a good response 12 weeks after the onset of RT exhibited pain recurrence. Compared to 12 weeks after the onset of RT, 25 of the 119 patients (21%) with a good response within the 38-month follow-up exhibited pain recurrence.

Comparison of results for enthesopathies and arthrosis {#Sec13}
------------------------------------------------------

Treatment results comparing enthesopathies and arthrosis are given in Table [4](#Tab4){ref-type="table"}. In general, RT had a better effect on enthesopathies than on arthrosis.Table 4VAS scores and good responses in enthesopathies versus arthrosis at RT completion and follow-upEnthesopathies (*n* = 443)Arthrosis (*n* = 155)*P*-valueMedian VAS at RT completion (interquartile range)5.0 (3)5.0 (4)0.985Median VAS at follow-up (interquartile range)0.0 (3)4.0 (7)\<0.001Good response at RT completion, % (*n*/*N*)15.6 (69/443)14 (9/155)0.054Good response at follow-up, % (*n*/*N*)70.2 (331/443)40 (62/155)\<0.001

Comparison of sex {#Sec14}
-----------------

Results regarding biological sex are given in Table [5](#Tab5){ref-type="table"}. Efficacy immediately after RT (early response) was better in men than in women, but no significant difference was found at follow-up.Table 5Influence of sex on VAS scores and good responses at RT completion and follow-upFemale (*n* = 394)Male (*n* = 204)*P*-valueMedian VAS at RT completion (interquartile range)5.0 (4)5.0 (4)0.035Median VAS at follow-up (interquartile range)1.0 (5)0.5 (5)\<0.001Good response at RT completion, % (*n*/*N*)11.9% (47/394)17.6% (36/204)0.037Good response at follow-up, % (*n*/*N*)60.2% (237/394)66.7% (136/204)0.780

Multivariate analysis {#Sec15}
---------------------

The multivariate Cox regression analysis including sex, age, pre-treatment, disease group (enthesopathies or arthrosis), and number of treatment series revealed male gender (*p* = 0.031) and patients with enthesopathies (*p* \< 0.001) as significant prognostic factors for a good response at follow-up (Table [6](#Tab6){ref-type="table"}).Table 6Multivariate analysis of prognostic factors for a good response at follow-upFactorDistributionNumberGood response at follow-up (%)*P*-valueSexFemale/male394/20460.2/66.70.031Age\<62 years/≥62 years309/28965/59.50.374Pre-treatmentYes/No507/9162.7/60.40.920Disease groupEntesopathy/arthrosis443/15570.2/40\<0.001Number of seriesOne/two/three339/229/3064.3/59.4/63.30.774

Comparison of fractionation {#Sec16}
---------------------------

With regard to fractionation, we found no significant differences between 6 × 0.5 Gy and 10 × 0.5 Gy.

No side effects were observed.

Discussion {#Sec17}
==========

The results of our retrospective clinical quality assessment confirmed the results of recently published retrospective and prospective randomized studies showing a good analgesic effect of low-dose RT in patients with enthesopathies or arthrosis \[[@CR4]--[@CR13]\]. The pathophysiological mechanisms of pain relief after RT are most likely multifactorial. Radiobiological experiments clearly indicate that low-dose RT has an anti-inflammatory effect due to the modulation of a variety of inflammatory pathways and the influence on cellular components, such as endothelial cells, mononuclear and polynuclear leukocytes, and macrophages. An influence of the vascular endothelium, with improved tissue perfusion, destruction of inflammatory cells (especially lymphocytes) and release of cytokines and proteolytic enzymes, modulation of the autonomic nervous system, a change in tissue pH, and increased membrane permeability, has been demonstrated previously in experimental studies \[[@CR2]\].

Compared to the results immediately after RT, we observed a significant improvement in efficacy in the long term, confirming the results of other comparable studies. The relevant radiobiological mechanisms could cause the delayed clinical onset \[[@CR2], [@CR12], [@CR13]\].

Similar to recently published results, our data show a significantly better response to RT in patients with enthesopathies than in patients with arthritis \[[@CR12], [@CR13]\]. Arthroses reflect irreversible pathological processes in which cartilaginous and bony destruction occurs that cannot be reversed by radiotherapy. This irreversible destruction can trigger inflammatory processes, which then appear clinically as activated osteoarthritis with pain and swelling. During these episodes of pain, low-dose RT may be helpful due to known radiobiological mechanisms. The arthrosis itself remains, despite the improvement in pain. Therefore, the analgesic effect on arthrosis is only moderate compared to the analgesic effect on enthesopathies.

Furthermore, the significantly better response to RT in men compared to women confirms the well-known evidence of general differences between men and women in terms of pain perception and pain assessment \[[@CR14]\].

With regard to the number of treatment series in the same treatment region, the results of the patients who received two or three series are worse. Therefore, in the future, we will make the indication for low-dose radiotherapy strict in the case of repeated treatment series, because non-responders do not substantially benefit from additional treatment series.

A possible placebo effect of low-dose RT for the treatment of pain cannot be completely ruled out. Two randomized, blinded, and sham-controlled trials on knee and hand joint osteoarthritis were published recently and showed no significant difference in remission for RT groups compared to placebo groups \[[@CR15], [@CR16]\]. Despite the good study design, both studies are open to critique because of low patient numbers, short follow-up (3 months), and presumption of a very optimistic prognosis for the assessment of success. In addition, approximately 50% of the included patients had experienced pain ≥5 years before RT. In the future, randomized trials should include more patients, include patients with less advanced arthrosis and shorter duration of pain, and have a longer follow-up \[[@CR17]\].

Side effects did not occur in any of our patients. This confirms the relevant results in the literature \[[@CR4]--[@CR13]\].

With respect to the comparison of 6 × 0.5 Gy (*n* = 34) and 10 × 0.5 Gy (*n* = 564), we found no significant advantages of any of the fractionation schemes. Therefore, in the future, for radiation protection, irradiation should be performed according to the recommended German guidelines: enthesopathies and trochanteric syndrome with single doses of 0.5 to 1.0 Gy up to a total dose of 3.0 Gy, and arthrosis with single doses of 0.5 to 1.0 Gy up to a total dose of 3.0 to 6.0 Gy \[[@CR4]\].

Due to the known cancer risk, the indication for irradiation in patients younger than 40 years should be very critical. However, in older patients, the cancer risk can be neglected because it is low compared to the improvement in quality of life.

The limitations of our evaluation are the lack of randomization and blinding. Nevertheless, the crucial strength of the analysis is the long follow-up. Importantly, our analysis shows that low-dose RT of benign musculoskeletal diseases plays a very important, tendentially increasing, role in the context of health care in Germany in view of the aging population.

Conclusion {#Sec18}
==========

Low-dose RT is a very effective treatment for the management of painful benign skeletal disorders. In the present study, 62.4% of patients achieved a longer-lasting significant improvement in their quality of life. Due to the delayed onset of analgesic effects, low-dose RT results in significantly improved long-term efficacy compared to the results immediately after RT. In general, RT had a better effect on enthesopathies than on arthrosis. The results of our retrospective clinical quality assessment confirm the results of other retrospective, prospective, and randomized trials.
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